Facial Basal Cell Carcinoma Treated with Topical 5% Imiquimod Cream with Dermoscopic Evaluation
暂无分享,去创建一个
[1] A. Marzuka,et al. Basal Cell Carcinoma: Pathogenesis, Epidemiology, Clinical Features, Diagnosis, Histopathology, and Management , 2015, The Yale journal of biology and medicine.
[2] J. Carucci,et al. Advances in the management of basal cell carcinoma , 2015, F1000prime reports.
[3] Chen Li-hua,et al. Successful Treatment of Giant Basal Cell Carcinoma with Topical Imiquimod 5% Cream with Long Term Follow-up , 2014, Indian journal of dermatology.
[4] P. Carli,et al. In vivo characterization of the inflammatory infiltrate and apoptotic status in imiquimod‐treated basal cell carcinoma , 2009, International journal of dermatology.
[5] S. Ibbotson,et al. A randomized parallel study to assess the safety and efficacy of two different dosing regimens of 5% imiquimod in the treatment of superficial basal cell carcinoma , 2008, The Journal of dermatological treatment.
[6] S. Rosso,et al. FULL PAPER , 2020, VALUE.
[7] C. Ferrándiz,et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from a randomized vehicle‐controlled phase III study in Europe , 2005, The British journal of dermatology.
[8] L. Golitz,et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies. , 2004, Journal of the American Academy of Dermatology.
[9] H. Williams,et al. Surgical excision versus imiquimod 5% cream for nodular and superficial basal-cell carcinoma (SINS): a multicentre, non-inferiority, randomised controlled trial. , 2014, The Lancet. Oncology.